Swing

Swing Therapeutics is a digital therapeutics company that develops software-based treatments and services for chronic conditions, with a focus on autoimmune conditions and chronic overlapping pain conditions such as fibromyalgia, where central pain sensitization is a significant factor. Its two principal offerings are Stanza, a prescription digital behavioral therapy for adults managing fibromyalgia symptoms, and Swing Care, a virtual specialty clinic dedicated to comprehensive fibromyalgia treatment.

Stanza delivers a self-guided behavioral program based on acceptance and commitment therapy through a smartphone application, structured as approximately 15 minutes of daily use over a 12-week course. The company positions the therapy as a non-drug option and reports that no treatment-related safety events were observed in its clinical studies. Swing Therapeutics states that it develops disease-specific programs using proprietary software, conducts its own research to validate treatments, and works with a panel of external clinical and patient-advocacy advisors.

The company's research program spans pilot, pivotal, real-world and long-term extension studies, including the SMART-FM phase II pilot trial and the PROSPER-FM phase 3 randomized controlled trial, whose results were published in The Lancet. Additional published work covers usability and acceptability, clinical impact in a decentralized trial, long-term effectiveness through 12 months, healthcare cost savings and reduced work absenteeism, and early outcomes from the Swing Care telehealth clinic.

Founding story

The company was founded in 2019 with the goal of developing digital treatments and services in disease areas where patients are not well served, targeting autoimmune conditions and chronic overlapping pain conditions such as fibromyalgia in which central pain sensitization plays a significant role.

Business model

Swing Therapeutics commercializes prescription digital therapeutics and an associated virtual specialty clinic. Stanza is a prescription product distributed to patients through clinicians, and the company has pursued payer coverage, including a positive coverage decision from Highmark. Swing Care operates as a telehealth specialty clinic delivering multi-modal fibromyalgia treatment inclusive of Stanza.

The company offers Stanza as a prescription digital therapy and Swing Care as a virtual clinic; payer reimbursement is part of its access approach, evidenced by a Highmark coverage decision for Stanza.

Traction

Stanza obtained FDA De Novo marketing authorization and became commercially available; positive pivotal phase 3 results were announced and published in The Lancet; a 12-month extension study reported durable benefits; a real-world trial and early Swing Care clinic outcomes were presented; and Highmark issued a positive coverage decision for Stanza.

Latest developments

Recent company announcements include follow-up and 12-month extension results from the PROSPER-FM study showing durable benefits of Stanza, The Lancet publication of the phase 3 trial data, real-world evidence on unmet patient needs, early outcomes from the Swing Care specialty clinic, and Highmark coverage for Stanza. A securities filing reported in August 2025 indicates an $11.4 million raise as part of a $14.6 million offering.